Democritus University of Thrace (DUTH)
Μελέτη της κατάστασης μεθυλίωσης ογκοκατασταλτικών γονιδίων στο cell free DNA (cfDNA) ασθενών με πρώιμο και προχωρημένο καρκίνο παγκρέατος: αναζήτηση της προγνωστικής και προβλεπτικής τους σημασίας
Abstract
dc:descriptionPancreatic cancer (PC) is a frequent malignancy, the number of PC cases has been multiplied over the past two decades. Based on prognostications, PC is expected to become the third leading cause of cancer-related deaths in the Europe. This highly mortality rate is caused by late diagnosis and treatment failure. Due to the lack of early manifestations, the majority of the PCAC patients discover the disease when it is advanced or already metastatic. There is a great need of simple and standard, minimally invasive test that can monitor those altered genes or their associated pathways in time for the success of precision medicine, and liquid biopsy is a promising answer to all these questions. In this study we have focus our interest indetecting and quantifying circulating DNA (cfDNA), one of the most important components of liquid biopsy. More specifically, we have tried to detect the epigenetic aspect of cfDNA in combination with its concentration in order to define new possible prognostic indicators. Using methylation specific PCR we examined the methylation status of SOX17, RASSF1A, BRCA1, BRCA2 in 55 patients with operable and 50 patients with metastatic pancreatic cancer at the department of Medical Oncology in the University General Hospital of Alexandroupolis. The results are: The patients with methylation of promoter of SOX17, RASSF1A, BRCA1 have a statistically significant poorer overall survival and progression free survival as compared with patients with a non-methylated one in metastatic disease. The patients with methylation of promoter of BRCA1, BRCA2 have a statistically significant poorer overall survival and disease free interval as compared with patients with a non-methylated one in early disease. Patients with cfDNA concentration <0.5 ng/μL presented significant longer survival as compared with those having >0.5 ng/μL especially in patients with early disease (stage II).The patients with more than one methylated promoter of the genes SOX17, RASSF1A, BRCA1, BRCA2 had significant poorer survival rates. According to our knowledge our findings are strong evidences that cfDNA combined with DNA methylation markers have a prognostic potential. This evidence must be verified in a larger cohort of patients and must be potentialized by a more sensitive methodology.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Koukaki, Triantafyllia
- Κουκάκη, Τριανταφυλλιά
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/58397